LinkedIn: We are pleased to announce that a late-breaking abstract on BYN-002 has been accepted for presentation and publication at UEG Week 2026. The abstract, entitled: “BYN-002 (TL-001), A Next-Generation Anti-TL1A Antibody Demonstrating Potent Neutralization, Extended Pharmacokinetics, Durable TL1A Suppression and Favorable Immunogenicity: Interim Phase 1 SAD/MAD Results,” will be presented as an e-poster during […]
Read MoreMore Tag
Today marks an important step in Bionyra’s journey
LinkedIn: We are pleased to announce the successful completion of enrollment in the Single Ascending Dose (SAD) portion of the Phase 1 study of BYN-003, our next-generation bispecific TL1A × IL-23p19 monoclonal antibody. This achievement represents an important step in advancing our mission to develop transformative therapies for patients living with immune-mediated inflammatory diseases. We […]
Read MoreMore Tag